Nautilus Neurosciences Inc., Kowa deal

Nautilus acquired two diclofenac products from Kowa's Kowa Pharmaceuticals America Inc. subsidiary. The products include oral Cambia diclofenac powder, which FDA approved in June to treat acute migraine attacks with or without aura in adults; and PRO-571, a rapid-release diclofenac tablet using dynamic buffering technology (DBT) in Phase I testing to treat acute pain. Kowa will receive an undisclosed upfront payment and is eligible for milestones. Kowa gained the products through its 2008 acquisition of ProEthic Pharmaceuticals Inc., which originally had rights from Applied Pharma Research S.A. (Balerna, Switzerland). ...